Why the study?
Supraventricular tachycardia remains difficult to manage or treat, warranting updated information on its causes, epidemiology, pathophysiology, clinical symptoms, and current management.
This systematic review provides an update on the epidemiology, pathophysiology, clinical symptoms, and management of paroxysmal supraventricular tachycardia.
Background: Supraventricular tachycardia (SVT) is an arrhythmia originating in or above the atrioventricular (AV) node and is defined by a narrow complex (QRS < 120 milliseconds) at a rate > 100 beats per minute (bpm).The incidence of AV nodal re-entry tachycardia is 35 per 10,000 person-years or 2.29 per 1000 people.Methodology: A systematic review was carried out through various databases from January 2015 to February 2022, the search and selection of articles was carried out in journals indexed in English. Results:In the United States, it has been identified that the prevalence of supraventricular tachycardia ranges from 0.2%, presenting an incidence of approximately 1 to 3 cases per thousand patients.To date this type of condition remains difficult to manage or treat.Alternative therapies include the use of beta blockers and calcium channel blockers. Conclusion:This review offers updated and detailed information on the main causes of paroxysmal supraventricular tachycardia, as well as its epidemiological aspects, pathophysiological processes, clinical symptoms, and current management
No takes yet. Share an insight, caveat, or question.
Carlos Andrés Genes Vasquez (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: